3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
2
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
pembrolizumab
63
Nivolumab
44
atezolizumab
14
Docetaxel
10
Cyclophosphamide
10
Paclitaxel
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
9
avelumab
8
Specimen Handling
8
durvalumab
7
Radiosurgery
7
Cetuximab
7
spartalizumab
6
Radiotherapy
6
Immune Checkpoint Inhibitors
6
Interleukin-2
5
Carboplatin
5
fludarabine
4
cabozantinib
4
Trastuzumab
4
Sunitinib
4
Psychiatric Rehabilitation
4
Pemetrexed
4
Oxaliplatin
4
Fluorodeoxyglucose F18
4
Everolimus
4
Cisplatin
4
Capecitabine
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
entrectinib
×
Thoracic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA